Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study
CONTEXT AND OBJECTIVE: Hereditary angioedema (HAE) with C1 inhibitor deficiency manifests as recurrent episodes of edema involving the skin, upper respiratory tract and gastrointestinal tract. It can be lethal due to asphyxia. The aim here was to evaluate the response to therapy for these attacks us...
Main Authors: | Regis Albuquerque Campos, Solange Oliveira Rodrigues Valle, Alfeu Tavares França, Elisabete Cordeiro, Faradiba Sarquis Serpa, Yara Ferreira Mello, Teresinha Malheiros, Eliana Toledo, Elie Mansour, Gustavo Fusaro, Anete Sevciovic Grumach |
---|---|
Format: | Article |
Language: | English |
Published: |
Associação Paulista de Medicina
|
Series: | São Paulo Medical Journal |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802014000500261&lng=en&tlng=en |
Similar Items
-
Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
by: Werner Aberer, et al.
Published: (2017-07-01) -
Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
by: Teresa Caballero, et al.
Published: (2018-03-01) -
Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks
by: Michihiro Hide, et al.
Published: (2021-01-01) -
The Search for Biomarkers in Hereditary Angioedema
by: Allen P. Kaplan, et al.
Published: (2017-11-01) -
In Vitro Modeling of Bradykinin-Mediated Angioedema States
by: François Marceau, et al.
Published: (2020-08-01)